Johnson & Johnson Settles For $230M, Quits Opioid Business

Deal takes the pharmaceutical giant out of huge New York trial
By Liz MacGahan,  Newser Staff
Posted Jun 26, 2021 3:30 PM CDT
Johnson & Johnson Settles For $230M, Quits Opioid Business
File photo of New York Attorney General Letitia James.   (AP Photo/Richard Drew)

Johnson & Johnson is going out of the opioid business in the US. It's also going to pay the state of New York a $230 million settlement, the New York Times reports. The agreement takes them out of a trial of several pharmaceutical makers slated to start next week. The funds will be used to fund treatment and prevention programs in New York, state Attorney General Letitia James said. The opioid industry is facing more than 3,000 lawsuits nationwide, per the Times.

Johnson & Johnson's involvement in the trial centered around products made by its subsidiary Janssen—a Fentanyl patch and a painkiller with an anti-crush coating. The pharmaceutical giant released a statement asserting that the drugs were less than 1% of the market and that their promotion was "appropriate and responsible," the Washington Post reports. The company is still facing lawsuits in other states, NBC News reports. (More Johnson & Johnson stories.)

Get the news faster.
Tap to install our app.
Install the Newser News app
in two easy steps:
1. Tap in your navigation bar.
2. Tap to Add to Home Screen.